Statistik Asas
| LEI | 984500B839ED8XIK6792 |
| CIK | 27367 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Daxor Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Exhibit 99.1 Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN — August 7, 2025 – Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generat |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2025 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| July 1, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2025 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2024 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: September 30, 2024 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL G |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: July 31, 2024 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2024 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2024 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: November 30, 2023 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2023 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2023 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| March 25, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 25, 2024 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| March 25, 2024 |
Exhibit 99.1 Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN – March 25, 2024 - Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25/A NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☒ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☒ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☒ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| February 14, 2024 |
FOLEY FOLEY & LARDNER LLP ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414. |
|
| January 2, 2024 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN – January 2, 2024 - Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announce |
|
| January 2, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2024 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 27, 2023 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction of incorporation) (Commission File |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2023 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2023 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 26, 2023 |
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering Exhibit 99.1 Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) — DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offer |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 25, 2023 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 24, 2023 |
40-17F2 1 form40-17f2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2022 2. State identification Number: AL AK |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2/A Amendment No. 2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2022 2. State identification Number: AL AK AZ AR CA |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 /A Amendment No. 1 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2022 2. State identification Number: AL AK AZ AR CA |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2022 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| November 21, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 17, 2022 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| November 21, 2022 |
Exhibit 99.1 Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option Oak Ridge, TN?(GLOBE NEWSWIRE)?DAXOR CORPORATION (Nasdaq: DXR) (?Daxor?, or the ?Company?), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering consisting of 210,527 shares of i |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 30, 2022 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 30, 2022 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| June 29, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 30, 2021 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| February 2, 2022 |
Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 2, 2022 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS |
|
| February 2, 2022 |
Exhibit 99.1 Daxor Corporation Commences Trading on The NASDAQ Capital Market Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022 Oak Ridge, TN ? February 2, 2022 ? Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it commenced trading on the NASDAQ Capital Markets as of today, February 2, 2022 and will visit the Nasdaq Mar |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 30549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Daxor Corporation (Exact name of registrant as specified in its charter) New York 13-2682108 (State of incorporation or organization) (I.R.S. employer identification no.) 109 Meco Lane, Oak Ridge |
|
| February 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 811-22684 Daxor Corporation ? NYSE American Exchange (Exact name of registrant as specified in its charter, and name of Exchange where security is listed and/or registered) 109 Meco |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction of incorporation) (Commission File |
|
| January 20, 2022 |
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022 Exhibit 99 Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022 Oak Ridge, TN ? January 20, 2022 ? Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces that it will commence trading on The Nasdaq Capital Market effective at the opening of trading on February 2, 2022, transferring the listing of its common stock from the New York Stock Exchange - American. |
|
| January 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2022 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction of incorporation) (Commission File |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 30, 2021 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| December 15, 2021 |
40-17F2 1 form40-17f2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: September 30, 2021 2. State identification Number: AL AK |
|
| July 13, 2021 |
ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER?S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 July 13, 2021 VIA EDGAR SYSTEM Ms. Deborah L. O?Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-255212 and 811- |
|
| June 30, 2021 |
Submission of Matters to a Vote of Security Holders 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2021 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Emp |
|
| June 2, 2021 |
DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permi |
|
| May 6, 2021 |
Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2021 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Emplo |
|
| May 6, 2021 |
Exhibit 99.1 Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure Trial Utilizing the BVA-100? (Blood Volume Analyzer) with the United States Department of Veterans Affairs NEW YORK, May 6, 2021 ? Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announces the initiation of a mul |
|
| April 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2020 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| March 15, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2021 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| March 15, 2021 |
Exhibit 99.1 DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE NEW YORK, MARCH 15, 2021? Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a phase-two c |
|
| December 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2020 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: August 31, 2020 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA H |
|
| October 5, 2020 |
Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 5, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| October 5, 2020 |
Exhibit 99.1 New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020 NEW YORK, October 5, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, toda |
|
| September 16, 2020 |
File No. 333- As filed with the Securities and Exchange Commission on September 16, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Daxor Corporation (Exact name of registrant as specified in its charter) New York 13-2682108 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer I |
|
| September 16, 2020 |
Daxor Corporation 2020 Incentive Compensation Plan.* Exhibit 4.3 DAXOR CORPORATION 2020 INCENTIVE COMPENSATION PLAN 1. Purpose. The purpose of this 2020 Incentive Compensation Plan (the “Plan”) is to assist Daxor Corporation (the “Company”) in attracting, retaining, motivating and rewarding high-quality executives, employees and non-employee directors who provide services to the Company and/or its Subsidiaries (as defined below), if any, enabling su |
|
| July 21, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 20, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| July 21, 2020 |
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering Exhibit 99.1 Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE American: DXR) (“Daxor” or the “Company”), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into definitive agreements with se |
|
| July 16, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 16, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction of incorporation) (Commission File Num |
|
| July 16, 2020 |
Exhibit 99.1 DAXOR ANNOUNCES PROSPECTIVE RANDOMIZED CONTROL TRIAL AT DUKE UNIVERSITY MEDICAL CENTER TO GUIDE VOLUME TREATMENT IN HEART FAILURE PATIENTS Enrollment Commences Using the BVA-100® Diagnostic Blood Test NEW YORK, July 16, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measuremen |
|
| July 15, 2020 |
Exhibit 99.1 Daxor Announces Initiation of First-of-It’s-Kind Multicenter BVA-100® Study in Hospitalized Patients with COVID-19 COVID-19 Investigation Commences at NYU Langone Health with Daxor’s Blood Volume Analysis Technology NEW YORK, July 15, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood vo |
|
| July 15, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 15, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| July 13, 2020 |
Registration Nos. 333-224509 811-22684 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 [X] Pre-Effective Amendment No. [ ] Post-Effective Amendment No. 6 [X] and/or REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 [X] Amendment No. 11 [X] DAXOR CORPORATION (Exact Name of Registrant as Specifie |
|
| July 13, 2020 |
ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX www.foley.com WRITER’S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 July 13, 2020 VIA EDGAR SYSTEM Ms. Deborah L. O’Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, Form N-2, File Nos. 333-22450 |
|
| July 13, 2020 |
Opinion and Consent of Foley & Lardner LLP - Filed herewith. Exhibit (l) FOLEY & LARDNER LLP ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| July 13, 2020 |
Consent of WithumSmith+Brown, PC - Filed herewith. Exhibit (n) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the use in the Prospectus Supplement constituting a part of the Registration Statement on Form N-2 of our report dated February 28, 2020, relating to the financial statements of Daxor Corporation as of and for the year ended December 31, 2019 in that Prospectus and to the financial statements of Daxor Corporation as of and for the year ended December 31, 2018 incorporated by reference and to the references to us under the heading “Independent Registered Public Accounting Firm” in the Prospectus and under the heading “Independent Registered Public Accounting Firm” in the Statement of Additional Information, which is part of such Registration Statement. |
|
| July 1, 2020 |
Exhibit 99.1 Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors NEW YORK, June 30, 2020 — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointments of Dr. Henry D. Cremisi and Joy Goudie |
|
| July 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 25, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| May 6, 2020 |
Bret Shapiro Sr. Managing Partner,CORE IR 516-222-2560 Exhibit 99.1 About Daxor Corporation Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-speci |
|
| May 6, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 30, 2020 |
Consent of WithumSmith+Brown, PC - Filed herewith. Exhibit (n) CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form N-2 of our report dated February 28, 2020, relating to the financial statements of Daxor Corporation, which is incorporated by reference in that Prospectus, and to the references to us under the heading “Independent Registered Public Accounting Firm” in the Prospectus and under the heading “Independent Registered Public Accounting Firm” in the Statement of Additional Information, which is part of such Registration Statement. |
|
| April 30, 2020 |
Opinion and Consent of Foley & Lardner LLP - Filed herewith. Exhibit (l) FOLEY & LARDNER LLP ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| April 30, 2020 |
Registration Nos. 333-224509 811-22684 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 [X] Pre-Effective Amendment No. [ ] Post-Effective Amendment No. 5 [X] and/or REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 [X] Amendment No. 10 [X] DAXOR CORPORATION (Exact Name of Registrant as Specified |
|
| April 23, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 23, 2020 Daxor Corporation (Exact name of registrant as specified in its charter) New York 811-22684 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| April 23, 2020 |
Exhibit 99.1 Daxor Awarded $1.1 Million Contract from United States Department of Defense (DOD) for Rapid Portable Blood Volume Analyzer New York, NY, April 23, 2020 - Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that the United States Department of Defense (DOD) ha |
|
| March 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2019 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: September 30, 2019 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL G |
|
| October 16, 2019 |
DXR / Daxor Corp. N-Q - Quarterly Schedule of Portfolio Holdings - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2019 Date of Reporting Period: September 30, 2019 Item 1. |
|
| October 16, 2019 |
EX-99.A 2 ex-a.htm Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. I have reviewed this report on Form N-Q of Daxor Corporation 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary t |
|
| September 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: July 31, 2019 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| May 31, 2019 |
DEFR14A 1 defr14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Prelimin |
|
| May 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| May 24, 2019 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| May 24, 2019 |
DXR / Daxor Corp. N-Q - Quarterly Schedule of Portfolio Holdings - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2019 Date of Reporting Period: March 31, 2019 Item 1. |
|
| May 20, 2019 |
Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, NY 10118 May 20, 2019 Via EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| May 17, 2019 |
POS 8C 1 cmw97.htm Registration Nos. 333-224509 811-22684 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 [X] Pre-Effective Amendment No. [ ] Post-Effective Amendment No. 4 [X] and/or REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 [X] Amendment No. 9 [X] DAXOR CORPORATION (Exact Name of Regi |
|
| May 17, 2019 |
CORRESP 1 filename1.htm ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER'S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 May 17, 2019 VIA EDGAR SYSTEM Ms. Deborah L. O'Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File N |
|
| May 10, 2019 |
CORRESP 1 filename1.htm Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, NY 10118 May 10, 2019 Via EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Daxor Corporation – Post-Effective Amendment No. 3 to Registration Statement on Form N-2 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigne |
|
| May 10, 2019 |
May 10, 2019 ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE, SUITE 3800 MILWAUKEE, WISCONSIN 53202-5306 414. |
|
| May 10, 2019 |
ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER'S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 May 10, 2019 VIA EDGAR SYSTEM Ms. Deborah L. O'Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-224509 and 811-2 |
|
| May 10, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2/A Registration Nos. 333-224509 811-22684 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 [X] Pre-Effective Amendment No. [ ] Post-Effective Amendment No. 3 [X] and/or REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 [X] Amendment No. 8 [X] DAXOR CORPORATION (Exact Name of Registrant as Specified |
|
| May 3, 2019 |
See attached pdf |
|
| May 3, 2019 |
ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER'S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 May 3, 2019 VIA EDGAR SYSTEM Ms. Deborah L. O'Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-224509 and 811-22 |
|
| April 3, 2019 |
Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, NY 10118 April 2, 2019 Via EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| March 22, 2019 |
40-17F2 1 form40-17f2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2018 2. State identification Number: AL AK |
|
| March 14, 2019 |
POS 8C 1 formpos8c.htm Registration Nos. 333-224509 811-22684 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-2/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 [X] Pre-Effective Amendment No. [ ] Post-Effective Amendment No. 2 [X] and/or REGISTRATION STATEMENT UNDER THE INVESTMENT COMPANY ACT OF 1940 [X] Amendment No. 7 [X] DAXOR CORPORATION (Exact Name of |
|
| March 14, 2019 |
Consent of WithumSmith+Brown, PC – Filed herewith. CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form N-2/A of our report dated February 28, 2019, relating to the financial statements of Daxor Corporation, which is incorporated by reference in that Prospectus. |
|
| March 14, 2019 |
Opinion and Consent of Foley & Lardner LLP – Filed herewith. ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| March 14, 2019 |
ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| November 16, 2018 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| November 16, 2018 |
DXR / Daxor Corp. N-Q (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2018 Date of Reporting Period: September 30, 2018 Item 1. |
|
| October 31, 2018 |
500,000 Shares DAXOR CORPORATION Common Stock EQUITY DISTRIBUTION AGREEMENT October 31, 2018 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, California 92660 Ladies and Gentlemen: Daxor Corporation, a New York corporation (the “Company”), proposes to issue and sell through Roth Capital Partners, LLC, acting as agent and/or principal (the “Manager”), up to 500,000 shares of common stock (the “Shares”), par value $0. |
|
| October 31, 2018 |
Consent of WithumSmith+Brown, PC – Filed herewith. CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form N-2/A of our report dated February 27, 2018, relating to the financial statements of Daxor Corporation, which is incorporated by reference in that Prospectus. |
|
| October 31, 2018 |
As filed with the Securities and Exchange Commission on October 31, 2018 Registration Nos. |
|
| October 9, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: August 31, 2018 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA H |
|
| September 28, 2018 |
OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0060 Expires: July 31, 2021 Estimated average burden hours per response..7.71 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 9/27/2018 Daxor Corporation (Exact name of registrant as specified in its ch |
|
| September 28, 2018 |
Daxor Corporation Appoints Robert J. Michel as Chief Financial Officer Exhibit 99.1 Daxor Corporation Appoints Robert J. Michel as Chief Financial Officer NEW YORK – September 28, 2018 - Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced the appointment of Robert J. Michel, CPA, MBA as its new chief financial officer, effective September 28, |
|
| August 17, 2018 |
Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, NY 10118 August 17, 2018 Via EDGAR United States Securities and Exchange Commission 100 F Street, N. |
|
| August 16, 2018 |
ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| August 10, 2018 |
EXLANATORY NOTE We are resubmitting the letter dated August 7, 2018 to attach to it the SEC correspondence referenced therein. |
|
| August 7, 2018 |
ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER’S DIRECT LINE 414.297.5596 CLIENT/MATTER NUMBER 103159-0101 August 7, 2018 VIA EDGAR SYSTEM Ms. Deborah L. O’Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-2 |
|
| July 20, 2018 |
ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414.271.2400 TEL 414.297.4900 FAX WWW.FOLEY.COM WRITER’S DIRECT LINE CLIENT/MATTER NUMBER 103159-0101 July 20, 2018 VIA EDGAR SYSTEM Ms. Deborah L. O’Neal Ms. Christina DiAngelo Fettig U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-224509 and 811- |
|
| July 16, 2018 |
40-17F2 1 form40-17f2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: May 31, 2018 2. State identification Number: AL AK AZ AR |
|
| June 13, 2018 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of Daxor Corporation In planning and performing our audit of the financial statements of Daxor Corporation (the “Company”), as of and for the year ended December 31, 2017, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Company’s in |
|
| June 13, 2018 |
June 13, 2018 VIA EDGAR SYSTEM Ms. Deborah L. O’Neal Senior Counsel U.S. Securities and Exchange Commission Division of Investment Management Washington, DC 20549 Re: Daxor Corporation, File Nos. 333-224509 and 811-22684 Dear Ms. O’Neal: On behalf of our client, Daxor Corporation (“Daxor”), set forth below are Daxor’s responses to comments of the Staff (the “Staff”) of the Securities and Exchange |
|
| May 22, 2018 |
DAXOR CORPORATION 350 FIFTH AVENUE, SUITE 4740 NEW YORK, NY 10118 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 27, 2018 NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of DAXOR CORPORATION (the “Company”) will be held at the principal office of the Company, 350 Fifth Avenue (Empire State Building), Suite 4740, New York, New York 10118, on Wednesday, June 27, 2018 at 10:00 a. |
|
| May 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2/A Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 September 19, 2014 2. State identification Number: AL AK AZ AR CA CO C |
|
| May 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2/A Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 June 15, 2015 2. State identification Number: AL AK AZ AR CA CO CT DE |
|
| May 14, 2018 |
DXR / Daxor Corp. N-Q (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2018 Date of Reporting Period: March 31, 2018 Item 1. |
|
| May 14, 2018 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| May 14, 2018 |
See attached pdf for calculations |
|
| May 14, 2018 |
begin 644 filename3.pdf M)5!$1BTQ+C4*):;IS\0-"C0@,"!O8FH*/#P*+TQE;F=T:" U(# @4@HO1FEL M=&5R("]&;&%T941E8V]D90H^/@IS=')E86T-"GC:Q5I9;QS'$7[GKUA "# # MB,/I>QJ[^Y#$MBQ'AF63D&3'?E $ZK"IBY1,6E'RVU-7S]3L+J5>04; !^YT M]U155WUU=/6\/OC;R<'15V:1.I,7)X\/S**'/[,P(7:#6Z0^='%Q\OS@G\T/ M[:'O)OCY97OHNJ&YWQX.G2O_;K<.UN*J^^TO)]\DV>&ADYXP\:)M_8*2(X*K5QE*$V5CKXB&.3).4 ML;PR5MI#DS,>K,E,F@PU1)S#<*B)'"*1H?$#$ |
|
| May 9, 2018 |
See attached pdf for calculations See attached pdf for calculations |
|
| May 9, 2018 |
May 9, 2018 ATTORNEYS AT LAW 777 EAST WISCONSIN AVENUE MILWAUKEE, WI 53202-5306 414. |
|
| May 9, 2018 |
NET ASSETS SHARES O/S 12/31/2016 15,344,309 3,798,463 4.04 12/31/2017 13,757,620 3,737,049 3.68 (0.36) $ change 3.62 AVERAGE 14,550,965 3.86 -9.28% change/(average shares) average 3,767,756 NAV Begin 4.04 Net investment income 274,759 0.07 0.07 net realized and unrealized on investments, options and securities borrowed 850,831 0.23 0.23 net realized and unrealized on operating division (2,340,866) |
|
| April 27, 2018 |
ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| March 15, 2018 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D. |
|
| March 9, 2018 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101 Washington, D. |
|
| March 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2017 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| February 28, 2018 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of Daxor Corporation In planning and performing our audit of the financial statements of Daxor Corporation (the ?Company?), as of and for the year ended December 31, 2017, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Company?s in |
|
| January 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 15, 2016 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| January 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 28, 2016 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| December 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: October 31, 2017 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| November 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant?s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2017 Date of Reporting Period: September 30, 2017 Item 1. |
|
| November 28, 2017 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| November 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, fo |
|
| September 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: July 12, 2017 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| May 16, 2017 |
Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics 8-K 1 form8-k.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0060 Expires: March 31, 2018 Estimated average burden hours per response……..5.71 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 5/16/2017 Daxor Corporation (Exact name of registrant a |
|
| May 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant?s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2017 Date of Reporting Period: March 31, 2017 Item 1. |
|
| May 8, 2017 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| April 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 31, 2016 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| April 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: December 28, 2016 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA |
|
| April 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: June 15, 2016 2. State identification Number: AL AK AZ AR CA CO CT DE DC FL GA HI |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [X] Form N-CSR For Period Ended: December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran |
|
| February 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [X] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2016 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tran |
|
| February 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): FEBRUARY 15, 2017 DAXOR CORPORATION (Exact name of registrant as specified in its charter) NEW YORK 0-12248 13-2682108 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 29, 2016 |
Daxor (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 4740 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2016 Date of Reporting Period: September 30, 2016 Item 1. |
|
| November 29, 2016 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| September 27, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): SEPTEMBER 22, 2016 DAXOR CORPORATION (Exact name of registrant as specified in its charter) NEW YORK 0-12248 13-2682108 (State or Other Jurisdiction of Incorporation |
|
| September 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): SEPTEMBER 22, 2016 DAXOR CORPORATION (Exact name of registrant as specified in its charter) NEW YORK 0-12248 13-2682108 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D x Form N-SAR o Form N-CSR For Period Ended: June 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| August 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR x Form N-CSR For Period Ended: June 30, 2016 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q |
|
| July 7, 2016 |
8-K 1 daxor8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2016 DAXOR CORPORATION (Exact name of registrant as specified in its charter) New York 0-12248 13-2682108 (State or other jurisdiction of |
|
| May 23, 2016 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Michael Feldschuh, certify that: 1. |
|
| May 23, 2016 |
Daxor FORM N-Q (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) Michael Feldschuh, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2016 Date of Reporting Period: March 31, 2016 Item 1. |
|
| May 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 15, 2016 |
Report of Independent Registered Public Accounting Firm EX-99.77(B) 2 ex9977b.htm EXHIBIT 99.77(B) Exhibit 99.77(b) Report of Independent Registered Public Accounting Firm To the Board of Directors of Daxor Inc. In planning and performing our audit of the financial statements of Daxor Inc. (the Company) as of and for the year ended December 31, 2015, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we c |
|
| March 15, 2016 |
Report of Independent Registered Public Accounting Firm Exhibit 99.77(b) Report of Independent Registered Public Accounting Firm To the Board of Directors of Daxor Inc. In planning and performing our audit of the financial statements of Daxor Inc. (the Company) as of and for the year ended December 31, 2014, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Company's internal control ov |
|
| March 15, 2016 |
Report of Independent Registered Public Accounting Firm Exhibit 99.77(b) Report of Independent Registered Public Accounting Firm To the Board of Directors of Daxor Inc. In planning and performing our audit of the financial statements of Daxor Inc. (the Company) as of and for the year ended December 31, 2013, in accordance with the standards of the Public Company Accounting Oversight Board (United States), we considered the Company's internal control ov |
|
| February 29, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D x Form N-SAR o Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form |
|
| February 29, 2016 |
NT-NCSR 1 daxorntncsr.htm NT-NCSR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 811-22684 NOTIFICATION OF LATE FILING (Check One): o Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR x Form N-CSR For Period Ended: December 31, 2015 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form |
|
| December 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 December 10, 2015 2. State identification Number: AL AK AZ AR CA CO CT D |
|
| November 24, 2015 |
Daxor FORM N-Q (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2015 Date of Reporting Period: September 30, 2015 Item 1. |
|
| November 24, 2015 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| November 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 October 1, 2015 2. State identification Number: AL AK AZ AR CA CO CT DE |
|
| September 1, 2015 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 99.77 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of Daxor Corporation We have audited the accompanying statement of assets and liabilities of Daxor Corporation (the ?Company?), including the schedule of investments, as of December 31, 2013, and the related statements of operations and cash flows for the year then ended and the stateme |
|
| June 29, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 June 15, 2015 2. State identification Number: AL AK AZ AR CA CO CT DE DC |
|
| June 22, 2015 |
June 22, 2015 ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414. |
|
| May 18, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| May 15, 2015 |
Daxor FORM N-Q (Quarterly Schedule of Portfolio Holdings) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant?s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2015 Date of Reporting Period: March 31, 2015 Item 1. |
|
| May 15, 2015 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| November 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2014 Date of Reporting Period: September 30, 2014 Item 1. |
|
| November 26, 2014 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| November 20, 2014 |
DXR / Daxor Corp. 40-17F2 - - FORM 40-17F2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 October 31, 2014 2. State identification Number: AL AK AZ AR CA CO CT DE |
|
| October 2, 2014 |
DXR / Daxor Corp. 40-17F2 - - FORM 40-17F2 40-17F2 1 rmsbg4017f2.htm FORM 40-17F2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 September 19, 2014 2. State ident |
|
| September 24, 2014 |
DXR / Daxor Corp. 40-17F2 - - FORM 40-17F2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-17f-2 Certificate of Accounting of Securities and Similar Investments in the Custody of Management Investment Companies Pursuant to Rule 17f-2 [17 CFR 270.17f-2] 1. Investment Company Act File Number: 811-22684 Date examination completed: 811-22684 August 12, 2014 2. State identification Number: AL AK AZ AR CA CO CT DE |
|
| May 23, 2014 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| May 23, 2014 |
Quarterly Schedule of Portfolio Holdings - FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2014 Date of Reporting Period: March 31, 2014 Item 1. |
|
| May 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| November 8, 2013 |
Quarterly Schedule of Portfolio Holdings - FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2013 Date of Reporting Period: September 30, 2013 Item 1. |
|
| November 8, 2013 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| September 16, 2013 |
September 16, 2013 ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414. |
|
| May 23, 2013 |
Quarterly Schedule of Portfolio Holdings - FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2013 Date of Reporting Period: March 31, 2013 Item 1. |
|
| May 23, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of |
|
| May 23, 2013 |
EX-99.A 2 exa.htm EXHIBIT A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Exhibit A I, Joseph Feldschuh, certify that: 1. I have reviewed this report of Form N-Q of Daxor Corporation 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact nec |
|
| May 10, 2013 |
May 6, 2013 ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414. |
|
| May 6, 2013 |
May 6, 2013 ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414. |
|
| November 15, 2012 |
Quarterly Schedule of Portfolio Holdings - FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31, 2012 Date of Reporting Period: September 30, 2012 Item 1. |
|
| November 15, 2012 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| November 9, 2012 |
November 9, 2012 ATTORNEYS AT LAW 777 East Wisconsin Avenue Milwaukee, WI 53202-5306 414. |
|
| June 28, 2012 |
June 28, 2012 ATTORNEYS AT LAW 777 East Wisconsin Avenue, Suite 3800 Milwaukee, Wisconsin 53202-5306 414. |
|
| June 19, 2012 |
Exhibit A CERTIFICATIONS PURSUANT TO RULE 30a-2(a) UNDER THE INVESTMENT COMPANY ACT OF 1940 AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Joseph Feldschuh, certify that: 1. |
|
| June 19, 2012 |
Quarterly Schedule of Portfolio Holdings - FORM N-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANIES INVESTMENT COMPANY ACT FILE NUMBER 811-22684 Daxor Corporation - (Exact name of registrant as specified in charter) 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Address of principal offices)(Zip code) David Frankel, Daxor Corporation 350 Fifth Avenue, Suite 7120 New York, New York 10118 (Name and address of agent for service) Registrant’s Telephone Number, including Area Code: 212-330-8500 Date of Fiscal Year End: December 31 Date of Reporting Period: March 31, 2012 Item 1. |
|
| June 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM N-8A NOTIFICATION OF REGISTRATION FILED PURSUANT TO SECTION 8(A) OF THE INVESTMENT COMPANY ACT OF 1940 The undersigned investment company hereby notifies the Securities and Exchange Commission that it registers under and pursuant to the provisions of Section 8(a) of the Investment Company Act of 1940, and in connection wi |
|
| March 30, 2012 |
Exhibit 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2011 Or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09999 Daxor Corporati |
|
| March 28, 2012 |
Exhibit 21.1 Subsidiaries of Registrant Name State of Organization Scientific Medical Systems Corp. New York |
|
| March 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K S ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2011 Or £ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09999 Daxor Corporation (Exact |
|
| November 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED September 30, 2011 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification N |
|
| August 31, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A (Amendment No. 1) Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED June 30, 2011 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer I |
|
| August 9, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED June 30, 2011 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 3 |
|
| May 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED March 31, 2011 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) |
|
| April 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2010 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09999 Daxor Corporation (Exact |
|
| March 29, 2011 |
Subsidiaries of Registrant Name State of Organization Scientific Medical Systems Corp. New York Exhibit 21.1 Subsidiaries of Registrant Name State of Organization Scientific Medical Systems Corp. New York |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED September 30, 2010 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification N |
|
| August 13, 2010 |
10-Q 1 daxor2q10.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED June 30, 2010 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. |
|
| May 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED March 31, 2010 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) |
|
| May 6, 2010 |
DAXOR CORPORATION 350 FIFTH AVENUE, SUITE 7120 NEW YORK, NY 10118 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD JUNE 23, 2010 NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of DAXOR CORPORATION (the ?Company?) will be held at the principal office of the Company, 350 Fifth Avenue (Empire State Building), Suite 7120, New York City, on Wednesday, June 23, 2010 at 10:00 a. |
|
| March 29, 2010 |
EX-10.1 25 ex101.htm EXHIBIT 10.1 EXHIBIT 10.1 |
|
| March 29, 2010 |
Subsidiaries of Registrant Name State of Organization Scientific Medical Systems Corp. New York Exhibit 21.1 Subsidiaries of Registrant Name State of Organization Scientific Medical Systems Corp. New York |
|
| March 29, 2010 |
Exhibit 4.1 |
|
| March 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2009 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-09999 Daxor Corporation (Exact |
|
| March 29, 2010 |
EXHIBIT 3.2 |
|
| November 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED September 30, 2009 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification N |
|
| August 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED June 30, 2009 Commission File Number 001-09999 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 3 |
|
| July 8, 2009 |
8-K 1 daxor8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2009 DAXOR CORPORATION (Exact Name as Specified in its Charter) Commission File Number 0-12248 New York 13-2682108 (State or Other Jurisdiction of ( |
|
| May 12, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED March 31, 2009 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 35 |
|
| May 8, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| March 23, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2008 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12248 Daxor Corporation (Exact na |
|
| November 13, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED SEPTEMBER 30, 2008 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No. |
|
| July 31, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED JUNE 30, 2008 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 350 |
|
| May 28, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of |
|
| May 15, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED MARCH 31, 2008 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 35 |
|
| March 31, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2007 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12248 Daxor Corporation (Exact na |
|
| November 14, 2007 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED SEPTEMBER 30, 2007 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 350 Fifth Av |
|
| August 9, 2007 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED JUNE 30, 2007 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 350 Fifth Ave Sui |
|
| May 15, 2007 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED MARCH 31, 2007 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 350 Fifth Ave Su |
|
| May 14, 2007 |
DAXOR CORPORATION 350 FIFTH AVENUE, SUITE 7120 NEW YORK, NY 10118 NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD JUNE 15, 2007 NOTICE IS HEREBY GIVEN that the Annual Meeting of Shareholders of DAXOR CORPORATION (the ?Company?) will be held at the principal office of the Company, 350 Fifth Avenue (Empire State Building), Suite 7120, New York City, on Friday, June 15, 2007 at 10:00 a. |
|
| April 2, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2006 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12248 Daxor Corporation (Exact na |
|
| January 24, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2007 DAXOR CORPORATION (Exact name of registrant as specified in this charter) NEW YORK 0-12248 13-2682108 (State or other jurisdiction of incorporation) (Commission File |
|
| December 22, 2006 |
Exhibit 99.1 Daxor Announces the Promotions of Stephen Feldschuh to Chief Operating Officer and David Frankel to Chief Financial Officer New York, NY - December 21, 2006 - Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced the promotions of Stephen Feldschuh to Chief Operating Officer (COO) and David Frankel to Chief Financial Officer (CFO). Stephen |
|
| December 22, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 21, 2006 DAXOR CORPORATION (Exact name of registrant as specified in this charter) NEW YORK 0-12248 13-2682108 (State or other jurisdiction of incorporation) (Commission File |
|
| November 15, 2006 |
DAXOR CORPORATION AND SUBSIDIARY TABLE OF CONTENTS 10-Q 1 d6989910-q.htm QUARTERLY REPORT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED SEPTEMBER 30, 2006 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organiz |
|
| November 9, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2005 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12248 Daxor Cor |
|
| October 18, 2006 |
October 17, 2006 Mr. Gary Todd United States Securities and Exchange Commission Division of Corporate Finance Mail Stop 6010 Washington, D.C. 20549 Dear Mr. Todd: As per our discussion, two draft copies of the Form 10-K/A are attached. One copy is labeled Daxor Revised 10-K Version 3 and has all changes accepted (this is the ?clean copy?). The second copy is labeled Daxor Revised 10-K Version 4 an |
|
| August 14, 2006 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED JUNE 30, 2006 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York (State or Other Jurisdiction of Incorporation or Organization) 13-2682108 (I.R.S. Employer Identification No.) 350 Fifth Ave Sui |
|
| May 22, 2006 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of the Securities Act of 1934 FOR QUARTER ENDED MARCH 31, 2006 Commission File Number 0-12248 DAXOR CORPORATION (Exact Name as Specified in its Charter) New York 13-2682108 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification No.) 350 Fifth Ave Su |
|
| April 28, 2006 |
SCHEDULE 14A SCHEDULE 14A INFORMATION SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2006 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES Exchange Act of 1934 For the fiscal year ended: December 31, 2005 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-12248 Daxor Corporation (Exact na |
|
| February 27, 2006 |
February 24, 2006 Mr. Gary Todd United States Securities and Exchange Commission Division of Corporate Finance Mail Stop 6010 Washington, D.C. 20549 Dear Mr. Todd: Thank you for granting us additional time to respond to your letter dated October 7, 2005. In response to the issues you raised we submit the following: Form 10-K as of December 31, 2004 1. We understand that the issue of the Company?s |
|
| September 27, 2005 |
1 September 15, 2005 Mr. Gary Todd Reviewing Accountant United States Securities & Exchange Commission 100 F. Street N.E., Mail Stop 0610 Washington, D.C. 20549 Dear Mr. Todd: We wish to express our appreciation to your office for permitting us additional time to answer your letter. With respect to the Investment Company Act, we have reviewed the relevant portions of the government document, 17 CF |
|
| August 26, 2005 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 August 26, 2005 Date of Report (Date of earliest event reported) DAXOR CORPORATION (Exact name of registrant as specified in this charter) NEW YORK 001-09999 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorporation) File |
|
| March 21, 2005 |
Changes in Registrant's Certifying Accountant SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 March 11, 2005 Date of Report (Date of earliest event reported) DAXOR CORPORATION (Exact name of registrant as specified in this charter) NEW YORK 001-09999 13-2682108 (State or other jurisdiction (Commission (IRS Employer of incorporation) File N |
